Objectives: To describe the role and current status of vaccine research against sexually transmitted diseases (STDs). Methods: The available literature was reviewed with particular emphasis on bacterial STDs. Results: Strategic approaches to possible implementation of STD vaccine programmes were analysed. The status of vaccines against bacterial STDs (syphilis, chancroid, gonorrhoea, and chlamydia) is described in detail. Conclusions: The development of safe and effective STD vaccines offers a potent tool for the control of STDs, including direct and indirect prevention of HIV infection. Future priorities should be in the development of vaccines against gonorrhoea, chlamydia, and syphilis. When such vaccines become available, caution should be exercised to ensure that they do not interfere with the effectiveness of other prevention programmes.
Sexually transmitted diseases (STDs) are a major public health problem in both developed and developing countries. Worldwide it is estimated that over 250 million cases of STDs occur annually, and prevalence rates appear to be far higher in developing countries where STD treatment is less accessible. In many developing countries STDs rank among the top five conditions for which adults seek health care.' Today, there are over 20 pathogens classified as sexually transmitted. Over the past 20 years the focus has broadened beyond the traditional "venereal" diseases of gonorrhoea, syphilis, chancroid, lymphogranuloma venereum, and granuloma inguinale. Concerns today include bacterial and viral syndromes associated with Chlamydia trachomatis, herpes simplex virus (HSV), and human papilloma virus (HPV).
Complications of STDs lead to increased morbidity and mortality in exposed adults and children. Gonorrhoea and chlamydia are the main causes of salpingitis, ectopic pregnancy, and infertility worldwide. Without preventive therapy up to 50% of babies exposed to Neisseria gonorrhoeae during birth develop ophthalmia neonatorum. In two thirds or more of pregnant women with syphilis, transplacental spread leads to severe outcomes such as spontaneous abortion, stillbirth, or perinatal death.2 Congenital syphilis is still an important problem in many parts of the world. HPV infection has been strongly associated with an increased risk of cervical cancer in women.3 If transmitted to the neonate at the time of vaginal birth, HPV can also cause neonatal and juvenile respiratory papillomatosis. 3 The preoccupation with STDs became even greater in the 1980s with the advent of the acquired immunodeficiency syndrome (AIDS) caused by the human immunodeficiency virus (HIV). In addition, antimicrobial resistance is a major problem in infections with Neisseria gonorrhoeae and Haemophilus ducreyi, making some cheap and accessible treatment regimens ineffective, and thereby favouring the spread of these infections. 4 Furthermore, there is strong evidence that STDs (both ulcerative and non-ulcerative) are significant contributors to the spread of HIV. Genital ulcer disease ( Apart from the presence of abrasions in/on the reproductive organs or the rectum, agents causing STDs are most likely to infect via the mucosa in the majority of exposed people. It therefore seems logical to develop vaccines that are designed to be administered via the mucosa or to stimulate mucosal immunity to prevent or combat these infections.6 Although a range of information about mucosal immunity and the most effective ways to induce it have been described,6-8 most of this knowledge concerns the gut. Relatively little is known about mucosal immunity of the genitourinary tract. In developing a vaccine against an infectious agent, there are important factors which must be considered when determining the feasibility of such a vaccine, as previously described. 6 Among these factors are: (1) the nature of the organism (its complexity), (2) the nature of the infection (acute or chronic), (3) the host's ability to develop natural immunity after infection, (4) whether the organism is cultivatable, (5) the degree of antigenic diversity, and (6) years old, with priority to 15-25 years of age) to ensure rapid "mopping up" of those people at risk of infection; while (2) aiming at elimination by ensuring integration of vaccination into existing programmes, such as EPI, and school immunisation programmes to replace the "mopping up strategy" once those immunised at young ages reach sexual activity.
The objective of an STD prevention strategy through vaccination is STD prevention and control and prevention of HIV infection. Therefore, it is crucial that other STD control and HIV prevention interventions be maintained, even 33 Ideally, a chlamydial vaccine should induce neutralising mucosal antibody. In practice, mucosal immunity is difficult to sustain in the absence of replicating antigen. Recent studies show that guinea pigs infected intestinally with C psittaci are protected from challenge at both conjunctival and vaginal mucosae." The delivery of MOMP antigens to the intestinal mucosa might be accomplished through oral vaccination with microencapsulated immunogens or with infectious enteric vaccine vectors (for example, attenuated salmonella strains) expressing MOMP immunogens.30 32 Most likely, in the absence of high concentrations of mucosal antibodies it will be difficult to prevent initial infection of host cells. After vaccination, high level of anti-chlamydia circulating antibody should be achieved easily and, following initial infection, might gain access to the epithelia by inflammatory transudation. Although not preventing initial infection, such antibody might be capable of neutralising released chlamydiae, modifying the severity of disease and decreasing individual infectivity in the community30 which, therefore, would reduce the high morbidity/sequelae associated with chlamydial infection.
Conclusion
STDs prevail as an important and costly public health problem worldwide. Owing to the serious morbidity and sequelae, priorities for vaccine development might be towards gonorrhoea, chlamydia, and syphilis. As research continues and much progress has been made towards vaccine development for most STDs, it is still not predictable when these vaccines will become available. The problem of stimulating long term immunity in the genital tract is still a challenge as little knowledge is available on genital tract immunology. Nevertheless, there are reasons for optimism. Until STD vaccines become available (and even when STD vaccines are delivered to the population), it is very necessary that other STD control and HIV prevention programmes be continued, as immunisation for STDs does not preclude the need for STD screening, treatment, and behavioural changes to reduce the risk of HIV transmission. On the other hand, efforts for vaccine development should remain in place since they are promising solutions for such important public health problems.
